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ABSTRACT 
Conventional medical treatments fail to address the underlying problems 
associated with the damage inflicted by a coronary event. Thus, the long-term 
prognosis of patients admitted for heart failure is disheartening, with reported 
survival rates of 25 percent. Recent advances in stem cell research highlight the 
potential benefits of autologous stem cell transplantation for stimulating repair in 
heart tissue. However, a majority of those suffering from cardiovascular diseases 
are older adults whose autologous cells no longer possess optimum functional 
capacity. Additional work is needed to identify the optimal cell types or conditions 
that will promote cardiovascular regeneration across all age groups. A 
pretreatment, such as short-term hypoxia, and concurrent implementation of a 
novel progenitor, such as those that co-express Isl-1 and c-Kit, may enhance the 
results reported in clinical trials completed to date. However, the effects of short-
term hypoxia in this novel cell type are unknown and warrant investigation in 
vitro. 
Cloned adult and neonatal Isl-1+ c-Kit+ human cardiovascular progenitor 
cells were characterized and expanded for study. Populations from both age 
groups were preconditioned using short-term hypoxia (1% O2 for six hours) and, 
to identify shifts in gene expression, compared to their respective control (21% 
O2 at 37 °C) via qRT-PCR. Flow cytometry and western blot analysis was utilized 
to measure phosphorylation of Akt. Progression through the cell cycle was also 
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analyzed by flow cytometry. Cellular function was evaluated by the use of a 
TUNEL assay and Transwell® invasion assay.  
Hypoxia-mediated alterations of a genetic or functional nature in Isl-1+ c-
Kit+ human cardiac progenitors are clearly age-dependent. Although both age 
groups accrued benefit, the neonatal progenitors procured significantly greater 
improvements. Short-term hypoxia significantly elevated Akt phosphorylation in 
neonatal Isl-1+ c-Kit+ human cardiac progenitors. Benefits afforded to both age 
groups by hypoxic pretreatment included significant upregulation of pro-survival 
transcripts, and enhanced invasion capabilities in vitro.  
Therefore, prior to transplantation, hypoxic preconditioning may improve 
the ability of transplanted stem cells to home towards damaged areas of the 
heart and support cardiac regeneration in vivo.  
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CHAPTER ONE 
INTRODUCTION 
 
  
Background 
Etiology and Global Impact of Cardiovascular Diseases 
Cardiovascular diseases (CVDs) encompass a suite of diseases that 
affect the heart and its vessels, the most common disease being coronary artery 
disease (CAD). CAD is typified by atherogenesis (plaque accretion) and 
subsequent lesion formation, both stenotic and non-stenotic, within the coronary 
artery. Stenotic lesions innately restrict blood flow by growing towards the lumen, 
but tend to have smaller lipid cores and thick fibrous caps that are not very 
susceptible to rupture (Libby & Theroux, 2005). On the other hand, a non-
stenotic lesion develops abluminally and, therefore, does not inherently affect 
coronary circulation until the constitutive lipid-rich core and thin fibrous cap are 
disturbed, initiating coronary thrombosis and occlusion (Libby & Theroux, 2005).
 Despite our comprehensive understanding regarding the etiology of CVDs, 
they remain the number one cause of death across the globe – accounting for 
approximately one out of every three deaths worldwide (Deaton et al., 2011; 
Mozaffarian et al., 2015). Additionally, patients hospitalized for heart failure 
typically develop permanent scarring of the heart and significant loss of 
cardiovascular function. Traditional treatments fail to address this issue and, as a 
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result, the long-term outlook of these patients is abysmal, with five-year survival 
rates lower than that of most cancer patients (Stewart, MacIntyre, Hole, 
Capewell, & McMurray, 2001). Public health efforts to curb the prevalence of 
CVDs have been largely focused on raising awareness of the many risk factors 
that are strongly correlated to the development of CVDs. Indeed, CVDs are 
highly preventable. Eliminating major CVD risk factors, which are mainly a result 
of poor lifestyle behaviors, results in up to a 90 percent lower lifetime CVD risk 
(McGill, McMahan, & Gidding, 2008). Unsurprisingly, as public awareness and 
use of evidence-based medical therapies for secondary prevention increased, 
the number of deaths in the United States attributed to CVDs (from 2001 to 2011) 
decreased by 30.8 percent, yet remained alarmingly high at approximately 
600,000 deaths per year (Mozaffarian et al., 2015). Therefore, while much 
progress has been made through raising of public awareness, the extreme 
burden of CVDs on worldwide human health will likely continue to persist lest 
novel treatments are developed that can repair the damaged caused by infarction 
and significantly lessen the associated mortality.  
Cardiovascular Stem Cell-based Therapy for the Injured Heart 
Although cardiac stem cells were known to be prevalent within the 
neonate heart, the notion that these cells steadily diminish and senesce into 
adulthood was widely accepted and, thus, the adult human heart was designated 
a terminally differentiated organ with no regenerative capabilities. With little 
evidence to suggest otherwise, early clinical trials for the treatment of myocardial 
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injuries primarily focused on bone marrow-derived cells for stimulating 
cardiovascular repair. However, the discovery that the adult human heart indeed 
houses populations of stem cells that support its regeneration (Beltrami et al., 
2003), prompted investigators to shift their focus onto transplantation of cardiac 
progenitor cells (CPCs) for the treatment of myocardial infarction.  
The potential benefits of endogenous CPC transplantation as a means of 
stimulating repair in heart tissue are currently under investigation with 
encouraging results in clinical trials (Bolli et al., 2011; Gerbin & Murry, 2015; 
Makkar et al., 2012). Phase I clinical research studies completed to date, 
examining the safety and feasibility of CPC transplantation, have noted little to no 
adverse effects resulting from cardiovascular infusion of stem cells, and, thus, 
the procedure is considered safe by clinicians. Most notably, investigators have 
reported significant reductions in total scar tissue and significant improvements in 
left ventricular ejection fraction –  progressing even after 12 months post-op (Bolli 
et al., 2011; Makkar et al., 2012). However, it has been demonstrated that, 
although transplanted CPCs alleviate some cardiovascular dysfunction, they fail 
to engraft and differentiate into new myocardium (Hong et al., 2014). Therefore, it 
is believed that the observed reductions in scar size and improvements in cardiac 
function – typically measured using left ventricular ejection fraction – are a result 
of paracrine signaling stemming from growth factors secreted by newly 
transplanted cells (Barile et al., 2014). Furthermore, autologous stem cells 
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derived from adult patients are known to lack the functional potency of their 
neonatal counterparts (T. I. Fuentes et al., 2013). 
 Due to the correlation between incidence of CVDs and age, older adults, 
by way of sheer numbers, are the group most in need of cell-based cardiac 
therapy. If adult autologous stem cells are unable to impart significant functional 
benefits after transplantation, then the overall application of autologous stem cell-
based therapies for treatment of cardiovascular injury may be drastically limited 
to treating neonatal heart diseases. Even so, stem cell-based therapies for the 
treatment of congenital heart diseases (CHDs) are of significant interest to 
clinicians. While the number of afflicted patients is relatively small in comparison 
to those suffering from adult CVD, CHDs occur in roughly one percent of live 
births worldwide and CHD incidence has increased in recent decades (Marelli, 
Mackie, Ionescu-Ittu, Rahme, & Pilote, 2007). Indeed, the mortality rate for CHDs 
is declining and more of those born with CHD are surviving into adulthood. 
However, data gathered between 2007 and 2010 reveals that CHD-related 
mortality for neonates is still a cause for concern at 10.1%. In the year 2011 
alone, mortality related to CHD in the U.S. was 4900 (Mozaffarian et al., 2015). 
Thus, CHDs remain responsible for more deaths than any other congenital birth 
defect. All too often, neonates suffering from a particularly severe heart 
malformation are in need of a heart transplant. Complete organ transplants are 
costly, invasive, and, most importantly, limited by the availability of donor organs. 
Hence, there has been a growing interest in stem cell-based therapies for 
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treating CHDs. Clinical trials completed to date have established the safety of 
stem cell transplantation for the treatment of hypoplastic left heart syndrome and 
other CHDs (Ishigami et al., 2015). However, much like the clinical trials that 
established the safety of stem cell therapy for CVDs in adults, further work is 
needed to improve post-operative outcomes.  
The effectiveness of cell-based treatments for the heart may be 
significantly improved by use of a novel cell type or pretreatment method, such 
as hypoxic exposure, that alters the function of adult-derived CPCs to mirror that 
of the more capable neonatal stem cells. Any benefits afforded to adult CPCs 
would also likely be procured by neonatal CPCs. However, additional work is 
needed to identify these optimal cell types or conditions that will promote 
autologous stem cell-mediated cardiovascular regeneration in the injured adult 
and neonatal human heart. To date, several potential preconditioning methods 
have been evaluated for their ability to augment cellular function. For instance, it 
has been demonstrated that pretreatment with growth factors enhances the 
therapeutic efficacy of mesenchymal stem cells for myocardial infarction (Hahn et 
al., 2008). Additionally, cobalt protoporphyrin pretreatment protects human 
embryonic stem cell-derived cardiomyocytes from oxidative stress (Luo et al., 
2014). However, the benefits afforded by any one preconditioning method may 
vary depending upon the characteristics of the cell type chosen for therapy. 
Interestingly, there is a growing body of evidence in support of a master heart 
progenitor that gives rise to all the cells in the developed adult heart (Kattman, 
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Huber, & Keller, 2006; Laugwitz, Moretti, Caron, Nakano, & Chien, 2007; Wu et 
al., 2006). The discovery, characterization, and subsequent implementation of 
this primordial heart cell would undoubtedly lead to improved patient outcomes 
following cell therapy. To date, several populations of resident CPCs have been 
identified within the human heart and are promising candidates for use in future 
studies (T. Fuentes & Kearns-Jonker, 2013).  
Optimizing Cell Type 
CPCs are capable of self-renewal, expansion, and differentiation into all 
three major cell types of the heart (Bu et al., 2009; Moretti et al., 2006). The Isl-
1+ c-Kit+ population represents one type of CPC that was initially found 
exclusively within fetal progenitor populations (Simpson et al., 2012). However, 
Isl-1+ c-Kit+ hCPCs were subsequently identified within endogenous progenitor 
populations isolated from human neonatal and adult cardiac tissue, as well as 
from sheep cardiac tissue, as reported by the Kearns-Jonker laboratory at Loma 
Linda (T. I. Fuentes et al., 2013; Hou et al., 2012). Isl-1 is a transcription factor 
that is required early in development for the survival, proliferation, and migration 
of CPCs into the primordial heart and, as a result, the developed heart is largely 
a product of Isl-1+ cells (Cai et al., 2003). Specifically, Isl-1+ CPCs play a critical 
role in early heart formation by contributing to the outflow tract, right atrium, right 
ventricle, and septum (Cai et al., 2003; Dodou, Verzi, Anderson, Xu, & Black, 
2004; Yang et al., 2013). One of the most widely studied progenitor cell types, 
however, is the c-Kit+ CPC. While current clinical trials using c-Kit+ cells show 
7 
promise, the role of c-Kit+ cells in the development and regeneration of the heart 
remains controversial (Cheng et al., 2014; Ferreira-Martins et al., 2012; Kubo et 
al., 2008; van Berlo et al., 2014; Zaruba, Soonpaa, Reuter, & Field, 2010). Isl-1+ 
c-Kit+ CPC populations, by virtue of their distinct protein fingerprint, may be 
inherently superior to those CPC populations expressing only Isl-1 or only c-Kit, 
and may be better suited for transplantation into the hypoxic heart. Moreover, this 
double-positive CPC population may react more strongly to preconditioning 
methods (aimed at enhancing cell function) when compared to single-positive 
CPCs. Thus, in order to surpass the results attributed to paracrine effects, and 
reach the desired levels of cardiovascular repair by direct engraftment, further 
investigation of Isl-1+ c-Kit+ CPCs is warranted. 
Hypoxic Preconditioning  
Using other models, previous studies have established that hypoxia 
treatment can boost cellular function through intracellular signaling pathways 
(Filippi et al., 2014; Hu et al., 2014; Studer et al., 2000; van Oorschot, Smits, 
Pardali, Doevendans, & Goumans, 2011; Yan et al., 2012). However, the effects 
of low oxygen tension on Isl-1+ c-Kit+ hCPC function have yet to be elucidated. 
Nonetheless, it is well understood that the partial pressure of oxygen in the 
tissues where CPCs reside, is much lower than in atmospheric air. Theoretically, 
the maximum amount of oxygen that can be bound by hemoglobin in the alveolar 
capillaries is approximately 21 percent by volume (mL O2/100 mL blood) or 159 
torr. However, because the rate at which hemoglobin binds and releases oxygen 
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is limiting, the maximum amount that can be bound per milliliter of blood is much 
lower, approximately 105 torr. Additionally, Fick’s law of diffusion applies at every 
point of gas exchange, thus further limiting the amount of oxygen that makes its 
way to the deep tissues of the heart per unit of time. Because of these limitations, 
by the time oxygen reaches the heart, its partial pressure can be as low as 30 
torr (Ivanovic, 2009). Furthermore, the heart houses small microenvironments, or 
niches, that support cardiac stem cells and play vital roles in the regulation of 
stem cell function (Li & Xie, 2005). While the tissues of the heart may experience 
a gradient of partial pressures, the innermost stem cell niches of the heart and 
their constituent CPCs are consistently hypoxic – with oxygen levels as low as 
1.0 percent, approximately 7.6 torr (Kimura & Sadek, 2012; Sanada et al., 2014; 
Tan et al., 2016).  
Accordingly, the impact of short-term hypoxia (six hours at 1.0 percent O2) 
on the in vitro biology of clonal Isl-1+ c-Kit+ hCPCs must be evaluated for 
pertinent information that will help optimize future transplant studies within animal 
models. Historically, in other cell types, Protein kinase B (Akt) expression 
increases in response to short-term hypoxia (Beitner-Johnson, Rust, Hsieh, & 
Millhorn, 2001) and is well-known to play vital roles in numerous cell functions 
including cell survival, proliferation, and chemotaxis (Manning & Cantley, 2007). 
An improvement in just one of these cellular processes may have a substantial 
effect on the overall efficacy of stem cell transplantation for cardiovascular 
therapy. Therefore, the hypothesis that short-term hypoxia upregulates Akt 
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phosphorylation in Isl-1+ c-Kit+ hCPCs and is correlated with enhanced cell 
function in vitro was tested. The combined benefits of using other progenitor cell 
types, such as those characterized by Isl-1, and pretreatment to prepare these 
transplanted cells for the hypoxic environment of the damaged heart, may allow 
for improved cardiac regeneration in vivo. 
Definition of Terms 
CVD: cardiovascular disease; CAD: coronary artery disease; CPC: cardiac 
progenitor cell; CHD: congenital heart disease; MEM NEAA: Minimum essential 
medium non-essential amino acids; DPBS: Dulbecco’s phosphate-buffered 
saline; qRT-PCR: Quantitative reverse transcription polymerase chain reaction; 
SDF-1α: Stromal cell-derived factor-1 α; SDS-PAGE: Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis; TUNEL: Terminal deoxynucleotidyl 
transferase deoxyuridine triphosphate nick-end labeling; PIK3CA: 
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α; HSP: Heat 
shock protein; MW: Molecular weight marker; ROS: Reactive oxygen species. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
 
In Vivo Components and Experiments 
Isolation and Culture of Isl-1+ c-Kit+ hCPCs 
The Institutional Review Board of Loma Linda University approved the 
protocol for use of tissue that was discarded during cardiovascular surgery, 
without identifiable private information, for this study with a waiver of informed 
consent. Isl-1+ c-Kit+ hCPCs were isolated from cardiac tissue as previously 
described (T. I. Fuentes et al., 2013). Briefly, atrial tissue was cut into small 
clumps (approximately 1.0 mm3) then enzymatically digested using collagenase 
(Roche, Indianapolis, IN) at a working concentration of 1.0 mg/mL. The resulting 
solution was then passed through a 40-µm cell strainer. Cells were then cloned in 
a 96-well plate by limiting dilution to a final concentration of 0.8 cells per well to 
create populations for expansion. Twelve hCPC clones, derived from six distinct 
donor samples, were used in this study. Clonal hCPC cultures were 
supplemented with growth media comprised of 10% fetal bovine serum (Thermo 
Scientific, Waltham, MA), 100 µg/mL Penicillin-Streptomycin (Life Technologies, 
Carlsbad, CA), 1.0% minimum essential medium non-essential amino acids 
solution (MEM NEAA, Cat no. 11120052, Life Technologies, Carlsbad, CA), and 
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20% endothelial cell growth media (Lonza, Basel, Switzerland) in Medium 199 
(Life Technologies, Carlsbad, CA).  
Hypoxic Preconditioning 
The day before hypoxic pretreatment, Isl-1+ c-Kit+ hCPCs received fresh 
culture media and, if necessary, were passaged to achieve 80% confluency 
within 24 hours. Experimental hCPCs were then placed in a Heracell™ 150 tri-
gas incubator (Thermo Scientific, Waltham, MA) set to 1.0% O2, 5.0% CO2, and 
94% N2 for six hours at 37 °C. Control hCPC conditions were 21% O2, 5.0% CO2, 
and 74% N2 at 37 °C. Cells were then immediately processed for analysis to 
avoid prolonged exposure to normoxic conditions.  
Transwell® Invasion Assay 
Cultrex® basement membrane extract (Trevigen, Gaithersburg, MD) was 
applied to the upper chamber of a Corning HTS Transwell® plate (8.0-µm pore 
size, Venlo, Limburg). Isl-1+ c-Kit+ hCPCs were suspended in starvation media 
composed of 98.5% Iscove's Modified Dulbecco's Medium with GlutaMAX™ (Life 
Technologies, Carlsbad, CA), 1.0% insulin-transferrin-selenium (Life 
Technologies, Carlsbad, CA), and 0.5% fetal bovine serum (Thermo Scientific, 
Waltham, MA) then plated onto the coated wells at a density of 50,000 cells per 
well. Stromal cell-derived factor-1α (SDF-1α, Life Technologies, Carlsbad, CA), a 
chemoattractant, was diluted with growth media to a final concentration of 100 
ng/mL and administered to the lower chamber. After 48 hours of incubation at 37 
°C, the cells in the lower chamber were dissociated, stained with calcein AM (BD 
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Biosciences, San Jose, CA), and analyzed using an FLx800™ microplate 
fluorescence reader (BioTek Instruments, Winooski, VT). 
 
In Vitro Assays 
Quantitative Reverse Transcription PCR 
Isl-1+ c-Kit+ hCPCs were washed with Dulbecco’s Phosphate-Buffered 
Saline (DPBS), then lysed using TRIzol® reagent (Life Technologies, Carlsbad, 
CA). Total RNA was isolated using the RNeasy® Mini Kit (Qiagen, Venlo, 
Limburg) and cDNA was prepared with superscript III (Life Technologies, 
Carlsbad, CA). Quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) was performed in triplicate using Go-Taq® qPCR Mastermix 
(Promega, Madison, WI). Measurements were recorded using the iCycler iQ™5 
PCR Thermal Cycler (Bio-Rad, Hercules, CA). Cycler settings were set to 94 °C 
for 10 minutes, 94 °C for 15 seconds, 52 - 56 °C (depending on the primer) for 60 
seconds, and 72 °C for 30 seconds for a total of 45 cycles. Human primers were 
created using the National Center for Biotechnology Information Primer-BLAST 
program as listed in Table 1. Relative gene expression data was analyzed using 
the comparative CT method (Schmittgen & Livak, 2008).  
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Table 1. Primer Sequences Used for qRT-PCR. 
PRIMER SEQUENCE 
ACTNB FWD TTT GAA TGA GCC TTC GTC CCC 
ACTNB REV GGT CTC AAG TCA GTG TAC AGG TAA GC 
BCL2 FWD TGC ACC TGA CGC CCT TCA C 
BCL2 REV AGA CAG CCA GGA GAA ATC AAA CAG 
T (Brachyury) FWD ACT GGA TGA AGG CTC CCG TCT CCT T 
T (Brachyury) REV CCA AGG CTG GAC CAA TTG TCA TGG G 
HMOX1 FWD CTC TCG AGC GTC CTC A 
HMOX1 REV TTG AGC ACC TGG CCC CCA GA 
HSP40 FWD TTT TCG GAG GGT CCA ACC CCT 
HSP40 REV TCT TGT TTG AGG CGG GAT GGC C 
HSP70 FWD TGA CCA AGA TGA AGG AGA TCG 
HSP70 REV GTC AAA GAT GAG CAC GTT GC 
HSP90 FWD GGA TTT GAG GGG AAG A 
HSP90 REV TGA GCT TTC ATG ATT C 
POU5F1 (Oct-4) FWD AAC CTG GAG TTT GTG CCA GGG TTT 
POU5F1 (Oct-4) REV TGA ACT TCA CCT TCC CTC CAA CCA 
PDGFRA FWD GCG CAA TCT GGA CAC TGG GA 
PDGFRA REV ATG GGG TAC TGC CAG CTC AC 
PIK3CA FWD AAC AAT GCC TCC ACG ACC AT 
PIK3CA REV TCA CGG TTG CCT ACT GGT TC 
RELA FWD GCG AGA GGA GCA CAG ATA CC 
RELA REV GGG GTT GTT GTT GGT CTG GA 
 
 
Western Blotting 
Protein immunoblots for Akt and phosphorylated Akt were prepared using 
protein from normoxic hCPCs and hCPCs exposed to 6 hours of hypoxia (1.0% 
O2). Additionally, blots for β-Actin and p-Akt were prepared using samples 
obtained from untreated normoxic controls, normoxic hCPCs treated with stromal 
cell-derived factor-1 α (SDF-1α), and hCPCs treated with both SDF-1α and 
hypoxia. Following 18 hours of serum deprivation, hCPCs were stimulated using 
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10 µg/mL of SDF-1α (Biolegend, San Diego, CA). Hypoxic groups were exposed 
to low oxygen conditions during the final six hours of the 18-hour starvation 
period. All protein lysates were loaded into a 12% Tris-glycine pre-cast gel 
(Thermo Scientific, Waltham, MA), separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), and transferred onto a 
nitrocellulose membrane (Bio-Rad, Hercules, CA). After blocking with 5% bovine 
serum albumin (BSA) in Tris-buffered saline with Tween-20 (TBST), membranes 
were labeled with mouse anti-human β-Actin antibody (2F1-1) (1:500 dilution, 
Biolegend, San Diego, CA), rabbit anti-human Akt monoclonal antibody (pan) 
(C67E7) (1:500 dilution Cell Signaling Technology, Danvers, MA), or rabbit anti-
human Phospho-Akt monoclonal antibody (S473) (D9E) (1:300 dilution, Cell 
Signaling Technology, Danvers, MA) overnight at 4 °C with agitation. The 
following day, membranes were washed and labeled using either an IRDye® 
680RD-conjugated goat anti-mouse antibody (1:5000 dilution, LI-COR, Lincoln, 
NE) or an IRDye® 800CW-conjugated goat anti-rabbit antibody (1:5000 dilution, 
LI-COR, Lincoln, NE) in 5.0% BSA in TBST for 60 minutes at room temperature. 
Final protein levels were visualized using an Odyssey® infrared imaging system 
(LI-COR, Lincoln, NE) model 9120. Resulting protein bands were analyzed using 
ImageJ software. 
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Flow Cytometry 
Progenitor cell populations were fluorescently labeled with antibodies as 
recommended by their respective manufacturers then analyzed using a 
MACSQuant® analyzer (Miltenyi Biotec, Auburn, CA). Quantification of data was 
performed using FlowJo software (Ashland, OR). Small particulate matter, dead 
cells, and gas-bubbles were excluded from final analysis using forward-scatter 
and side-scatter data.  
Antibodies Used in Cytometry Experiments 
Antibodies used for cytometric analysis include: Anti-Isl-1 (1H9) mouse 
monoclonal antibody, (1:50 dilution, Abcam, Cambridge, MA), Anti-c-Kit Rat 
IgG2b Kappa monoclonal antibody (2B8) conjugated to Dylight 650 (0.5 mg/mL, 
Novus Biologicals, Littleton, CO), Anti-Akt phospho (Serine 473) rabbit Ig 
polyclonal antibody (0.23 mg/mL, Biolegend, San Diego, CA), Fluorescein-anti-
BrdU (PRB-1) monoclonal antibody (1:20 dilution, Phoenix Flow Systems, San 
Diego, CA), FITC goat anti-mouse IgG polyclonal antibody (1:25 dilution, 
Southern Biotech, Birmingham, AL), PE goat anti-mouse IgG polyclonal antibody 
(1:100 dilution, Southern Biotech, Birmingham, AL), and FITC goat anti-rabbit 
IgG polyclonal antibody (1:50 dilution, BD Biosciences, San Jose, CA).  
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling 
Isl-1+ c-Kit+ hCPCs were rinsed with DPBS and treated with a solution of 
0.5 mM H2O2 in culture media for 21 hours to induce cell death (Clément, 
Ponton, & Pervaiz, 1998). Terminal deoxynucleotidyl transferase deoxyuridine 
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triphosphate nick-end labeling (TUNEL) assay was performed following the 
manufacturer’s recommendations. Briefly, cells were counted using trypan blue 
and concentrated to 106 cells/mL. The concentrated progenitor cell solution was 
then re-suspended in 1.0 mL of 1% paraformaldehyde in DPBS, placed on ice for 
30 minutes, then reconstituted into 1.0 mL of 70% ethanol for overnight 
incubation at -20 °C. The next day, the cells were labeled with Br-dUTP (Phoenix 
Flow Systems, San Diego, CA) and re-suspended in antibody solution containing 
the Fluorescein anti-BrdU antibody (Phoenix Flow Systems, San Diego, CA). 
Population analysis was performed using flow cytometry.  
Cell Cycle Analysis 
Isl-1+ c-Kit+ hCPCs at 80% confluency were trypsinized, counted, and 
concentrated to 2.5 X 105 cells per 0.3 mL DPBS. Ice-cold 70% ethanol (0.7 mL) 
was added drop-wise to fix the cells then stored at -20 °C overnight. The 
following day, cells were incubated at 37 °C for 1 hour with RNase A (0.5 mg/mL, 
Life Technologies, Carlsbad, CA). Propidium Iodide solution (0.5 mg/mL) was 
added, and the resulting cell solution was analyzed using a MACSQuant® 
analyzer (Miltenyi Biotec, Auburn, CA). Cytometer data was quantified using 
FlowJo software (Ashland, OR). 
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Statistical Analysis 
Data was reported as mean +/- standard error. Error bars were designed 
using propagation of error and the Cousineau method (Morey, 2008). P values < 
0.05 were deemed significant.  
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CHAPTER THREE 
RESULTS 
 
 
Akt Activation in Isl-1+ c-Kit+ hCPCs 
Hypoxic Preconditioning Stimulates the Akt Pathway  
in Isl-1+ c-Kit+ hCPCs 
Akt, a master regulator of numerous genes their corresponding proteins, 
oversees various critical cell processes such as apoptosis, proliferation, and 
chemotaxis (Manning & Cantley, 2007). To determine the effect of short-term 
hypoxia on the Akt pathway within Isl-1+ c-Kit+ hCPCs, clonal populations 
previously characterized by my laboratory colleagues (T. I. Fuentes et al., 2013), 
expressing Isl-1, c-Kit, Brachyury, Oct-4, and Platelet-derived growth factor 
receptor-α (PDGFRA, Fig.1A, B), were selected for experimentation. Enhanced 
Akt phosphorylation is of main interest for its potential benefit in autologous 
hCPC-based therapy for myocardial infarction in older adults. To determine 
whether the hypoxia-mediated activation of Akt is significantly influenced by the 
age of the cell donor, expression of phosphatidylinositol-4,5-bisphosphate 3-
kinase catalytic subunit α (PIK3CA), which is known to directly activate Akt (Baba 
et al., 2011), was measured via qRT-PCR in both control and experimental cells. 
Data analysis revealed that pretreated cells, regardless of age group, expressed 
significantly higher levels of PIK3CA mRNA when compared to non-treated, 
normoxic, Isl-1+ c-Kit+ hCPCs. Moreover, the data also shows that neonatal 
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hCPCs more strongly upregulate PIK3CA mRNA than do adult hCPCs and may 
lead to superior Akt activation in neonatal populations (Fig. 2A). Additionally, 
antibody labeling of activated Akt was measured by flow cytometry in adult and 
neonatal hCPC clones (Fig. 2B). Comparative analysis of the flow cytometry data 
gathered against phosphorylated Akt further highlights the distinction between 
the hypoxia-mediated activation of Akt in adult and neonatal Isl-1+ c-Kit+ hCPCs. 
While p-Akt expression indeed trends upwards in preconditioned adult clones, 
only the neonatal clones procured statistically significant elevations in Akt 
activation after preconditioning (Fig. 2C). However, the promise of short-term 
hypoxia preconditioning in adult Isl-1+ c-Kit+ hCPCs is illustrated via protein 
immunoblots (Fig. 3A). Quantification of the imaged protein from a single 
representative adult clone shows that phosphorylation of Akt can be promoted by 
exposure to short-term hypoxia (Fig. 3B). Moreover, serum starved adult Isl-1+ c-
Kit+ hCPCs show a significant decrease in phosphorylated Akt after stimulation 
with SDF-1α (Fig. 3C, D). However, when serum deprivation is conducted in 
tandem with short-term hypoxia and followed up with SDF-1α treatment, adult Isl-
1+ c-Kit+ hCPC p-Akt protein levels are rescued to levels at or above normoxic 
control, but not to a statistically significant degree (Fig. 3D).  
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Isl-1+ c-Kit+ hCPC Function After Exposure to Short-Term Hypoxia 
Isl-1+ c-Kit+ hCPCs Invade More Readily After Exposure  
to Short-term Hypoxia  
Hypoxia has also been shown to influence cellular motility (Filippi et al., 
2014; van Oorschot et al., 2011; Yan et al., 2012). To determine if short-term 
hypoxia has any effect on Isl-1+ c-Kit+ hCPC motility, and to validate the 
selection of the six-hour exposure time, the chemotactic response to SDF-1α 
amongst non-treated and pretreated hCPCs was compared using a Transwell® 
invasion assay. A time course experiment was performed in which a 
representative clone was pretreated with hypoxia for 3 hours, 6 hours, and 18 
hours for comparison of invasion capacities with normoxic control. Over the same 
48-hour incubation period, the six-hour hypoxia-pretreated group most efficiently 
invaded through the basement membrane layer and into the receiver well (Fig. 
4A). Using the six-hour time point across 10 different biological replicates, a 
statistically significant difference was noted between non-treated hCPCs and 
pretreated hCPCs. The hCPCs preconditioned with six hours of hypoxia invaded 
through the basement membrane extract and transwell pores in significantly 
greater numbers than the non-treated hCPCs (Fig. 4B). However, when the data 
is analyzed by age group, it is clear the adult hCPCs do not respond as 
vigorously to the hypoxia pretreatment. A trend towards enhanced invasion is 
present, but this trend is not significant. Only in the neonatal hCPCs did we 
observe a statistically significant hypoxia-mediated improvement in chemotactic 
response to SDF-1α (Fig. 4C). 
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Short-term Hypoxia Triggers a Pro-survival Response 
in Isl-1+ c-Kit+ hCPCs 
In other cell types, hypoxic pretreatment has been shown to improve 
survival (Hu et al., 2014; Yan et al., 2012). To determine the effect of short-term 
hypoxia on Isl-1+ c-Kit+ hCPCs, the expression profiles of several heat-shock 
proteins in control and experimental populations were examined using qRT-PCR. 
Data analysis confirmed that pretreated hCPCs indeed express higher levels of 
select heat-shock protein (HSP) mRNAs (Fig. 5A, B). However, only HSP70 is 
significantly upregulated by hypoxic preconditioning and only in neonatal clones 
(Fig. 5B). Subsequent electrophoresis of PCR products confirmed the 
upregulation of HSP70 in neonatal Isl-1+ c-Kit+ hCPCs via hypoxia 
preconditioning (Fig. 5C). Further gene expression analysis indicated that short-
term hypoxia not only induces a stress response but also significantly 
upregulates the transcription of genes associated with cell survival (Fig. 6A, B). 
However, only the neonatal group exhibited a significant change – an 
approximate twofold increase in the RELA gene transcript, known for its role in 
the regulation of apoptosis (Beg & Baltimore, 1996). If the data for both age 
groups is pooled, a threefold increase of Hemoxygenase 1 (HMOX1) is also 
noted (p = 0.04, n = 6). HMOX1 plays a role in protecting the cells from oxidative 
damage (Poss & Tonegawa, 1997). Within a six-hour timeframe, we found that 
the hypoxia-induced modifications to the pro-survival gene program resulted in 
fewer apoptotic cells in response to oxidative stress (Fig. 7A) However, 
quantification of results obtained from three independent adult clones revealed 
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little change in apoptotic response (Fig. 7B). TUNEL assay results from three 
individual neonatal hCPC populations reveal a downward trend in the number of 
apoptotic cells in response to H2O2 (Fig. 7C).  
Hypoxia-pretreated Isl-1+ c-Kit+ hCPCs Remain Undifferentiated 
To evaluate the effects of short-term hypoxia on differentiation in Isl-1+ c-
Kit+ hCPCs, the expression of several differentiation markers in control and 
experimental hCPCs was evaluated using qRT-PCR. Quantification of data 
revealed no significant difference between pretreated and non-treated adult 
hCPCs in two out of three markers examined (Fig. 8A). Only PDGFRA, present 
in sub-populations of progenitors with superior regenerative capacity (Hidaka et 
al., 2010; J. Kim et al., 2010) was significantly altered, upregulated 1.4-fold (p = 
0.004). In neonatal clones, a significant downregulation of Brachyury and 
upregulation of PDGFRA was noted (Fig. 8B). The Brachyury gene transcript is 
directly linked to the regulation of MESP1 (Robert David et al., 2011) a protein 
coding gene that promotes cardiovascular differentiation (R. David et al., 2008). 
Additionally, it is important to note that expression of the Oct-4 transcription 
factor remains unchanged in both age groups. Altogether, these findings suggest 
that short-term hypoxia stimulates neither differentiation nor de-differentiation in 
Isl-1+ c-Kit+ hCPCs.  
Hypoxia Pretreatment Does Not Alter Normal Cell Cycle Progression 
Hypoxia is also known to influence the cell cycle (Gardner et al., 2001; 
Grayson, Zhao, Bunnell, & Ma, 2007; Kook et al., 2008; Koshiji et al., 2004; 
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Studer et al., 2000; van Oorschot et al., 2011). A more proliferative stem cell 
population would undoubtedly be beneficial for the repair of damaged 
myocardium. To determine the effect of short-term hypoxia in regards to Isl-1+ c-
Kit+ hCPC proliferation, cell cycle analysis was performed on non-treated and 
pretreated hCPC populations of both adult and neonatal origin. No significant 
difference was identified between control and experimental groups (Fig. 9A). 
Moreover, there was no apparent difference between normoxic and hypoxic 
groups, whether adult and neonatal, in their progression through the cell cycle 
(Fig. 9B, C). These results support the conclusion that short-term hypoxia does 
not alter normal cell cycle progression in Isl-1+ c-Kit+ hCPCs.  
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CHAPTER FOUR 
DISCUSSION 
 
 
In this study, Isl-1+ c-Kit+ hCPCs were expanded as clonal populations 
and used as a model to test the hypothesis that short-term hypoxia exposure 
enhances Isl-1+ c-Kit+ hCPC function in vitro. The results presented here show 
that short-term hypoxia is a feasible and practical pretreatment that benefits 
neonatal hCPC invasive capabilities in vitro. 
Recent studies lend credence to the efficacy of cardiac stem cell 
transplants for the amelioration of cardiac dysfunction in mouse models (Hong et 
al., 2014; Matsuura et al., 2009). Furthermore, human trials have not only 
established the safety of autologous cardiac stem cell transplantation but also 
produced some very encouraging results (Bolli et al., 2011; Makkar et al., 2012). 
However, in both mice and human studies, improvements in cardiac function – 
typically measured using left ventricular ejection fraction – are thought to be a 
result of paracrine signaling stemming from the growth factors secreted by newly 
transplanted cells (Barile et al., 2014; Hong et al., 2014). Additionally, the 
functional capabilities of hCPCs are known to vary greatly between age groups 
with neonatal hCPCs consistently outperforming their adult counterparts (T. I. 
Fuentes et al., 2013). However, the incidence of cardiovascular disease is most 
prevalent within older adult hearts that are populated by functionally inferior 
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hCPC populations. Hence, administration of autologous hCPCs for treatment of 
the majority of cardiac injuries is limited, stimulates repair primarily by means 
other than direct engraftment, and leaves much to be desired. Cell-based 
therapies for the human heart – of all ages – may be augmented via the use of a 
novel cell type or pretreatment method, such as hypoxic exposure. If 
preconditioning indeed improves hCPC function, behavior of adult-derived clones 
could be selectively improved to reflect that of their functionally superior neonatal 
counterparts. However, CPC populations express distinct protein signatures that 
play an important role in overall cellular function and merit serious consideration 
when selecting cell populations for therapy. While the c-Kit+ CPC remains the 
most widely studied and implemented, the application of a novel Isl-1+ c-Kit+ 
hCPC population may aid in the effort to optimize autologous cell-based 
therapies for regeneration of the heart.  
The idea that preconditioning cells prior to transplantation may benefit 
donor cell function in vivo, has gained a significant following in recent years 
(Hahn et al., 2008; Hu et al., 2014; Luo et al., 2014; Rosenblum et al., 2014; van 
Oorschot et al., 2011; Yan et al., 2012). However, although this research is 
gaining momentum, the genetic analysis and functional assays presented in this 
study have never been performed on Isl-1+ c-Kit+ hCPCs. Using other models, 
previous studies have established that hypoxia induces a persistent increase in 
phosphorylation of Akt for up to 24 hours with the effect peaking at six hours 
(Beitner-Johnson et al., 2001). Activation of Akt, a versatile kinase that regulates 
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several cellular functions, may result in hCPC functional improvements and 
enhanced cardiac repair. In the present study, enhanced Akt phosphorylation 
was indeed observed after only six hours of hypoxia, thus demonstrating that Isl-
1+ c-Kit+ hCPCs exhibit similar behavior in response to hypoxia when compared 
to other cell types. However, age seems to play a significant role as the 
magnitude of hypoxia-mediated Akt activation was markedly reserved in adult 
clones. While both age groups displayed increased phosphorylation of Akt after 
the six-hour time point, only the neonatal group data was statistically significant. 
However, it is important to note that the adult clones are notoriously difficult to 
stimulate and, in response to SDF-1α after starvation, levels of p-Akt significantly 
decrease. Short-term hypoxic preconditioning, on the other hand, rescued 
previous levels of phosphorylated Akt observed prior to serum deprivation in 
adult Isl-1+ c-Kit+ hCPCs. As hypothesized, this hypoxia-mediated activation of 
Akt in Isl-1+ c-Kit+ hCPCs was indeed correlated with elevated expression of 
PIK3CA, a protein that plays an essential role in the upstream activation of Akt 
(Baba et al., 2011). Experimental neonatal Isl-1+ c-Kit+ hCPCs exhibited a 
remarkable 43-fold significant increase of PIK3CA mRNA when compared to 
their respective controls. Adult Isl-1+ c-Kit+ hCPCs, on the other hand, only 
expressed a 1.8-fold increase in PIK3CA mRNA due to hypoxic preconditioning. 
The data here suggests that neonatal Isl-1+ c-Kit+ hCPCs react more strongly to 
the hypoxic pretreatment and transcribe more of the upstream activator of Akt. 
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Altogether, these findings confirm that six hours of hypoxia exposure significantly 
increases Akt activation in neonatal Isl-1+ c-Kit+ hCPCs. 
Nonetheless, hypoxia is a stressor that, as demonstrated here, triggers a 
physiological response in hCPCs. As oxygen levels decline, the mitochondria 
within a cell increase the production of reactive oxygen species (ROS) (Chandel 
et al., 2000; Guzy et al., 2005). The accumulation of ROS after short periods of 
hypoxia has been shown to confer resistance against future oxygen shortages 
(Hoek, Becker, Shao, Li, & Schumacker, 1998). However, longer periods of 
hypoxia coincide with excessive accumulation of ROS that are known to promote 
cell death via caspase activation and DNA damage (Filomeni, De Zio, & Cecconi, 
2015; Kamata et al., 2005; J.-Y. Kim & Park, 2003; Moungjaroen et al., 2006). 
Altogether, chronic oxidative stress has the potential to impair the functional 
capacity and overall health of a population of cells (van Oorschot et al., 2011). 
The extent of this stress response in Isl-1+ c-Kit+ hCPCs was evaluated by 
measuring the impact of short-term hypoxia on the expression of several HSP 
mRNAs. The induction of the heat-shock pathway during hypoxia has been well 
documented in other cell types (Baird, Turnbull, & Johnson, 2006). Genetic 
analysis of adult and neonatal Isl-1+ c-Kit+ hCPCs revealed a trend towards 
hypoxia-mediated activation of transcripts for several heat shock proteins. 
However, only the upregulation of HSP70 mRNA was statistically significant and 
was found only in the neonatal group. HSP70 is known to play a role in stabilizing 
Akt (Koren et al., 2010) and in the inhibition of apoptosis (Jiang et al., 2009; 
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Powers, Clarke, & Workman, 2008). Under hypoxia, Akt and other proteins are at 
risk of degradation, thus, the survival response likely includes upregulation of 
HSP mRNAs as an attempt to promote stabilization of proteins that are needed 
for cell survival.  
Accordingly, pro-survival gene expression was also found to be 
upregulated in hypoxic Isl-1+ c-Kit+ hCPCs. Preconditioned hCPCs displayed a 
dramatic increase in transcripts encoding HMOX1, a pro-survival gene that 
becomes upregulated in response to hypoxia and affords protection against 
future oxidative damage (Poss & Tonegawa, 1997). Furthermore, the transcript 
encoding the NF-κB p65 subunit (RELA), a known Akt downstream effector that 
inhibits programmed cell death (Beg & Baltimore, 1996; Madrid, Mayo, Reuther, 
& Baldwin, 2001), was significantly upregulated, but only in the pretreated 
neonatal group. Although a significant difference in apoptosis was not observed, 
hypoxia-preconditioned hCPCs indeed exhibited significantly enhanced invasion 
capabilities when compared to their normoxic counterparts. Moreover, when 
additional time points were tested, the six-hour time point yielded the greatest 
number of cells that successfully invaded through the transwell membrane. 
Applied to multiple biological replicates, the six-hour pretreatment of hCPCs 
resulted in significantly improved chemotaxis in response to SDF-1α, which is in 
parallel to what has been observed in other models (Filippi et al., 2014; van 
Oorschot et al., 2011; Yan et al., 2012). Not surprisingly, however, these results 
were significant only in neonatal hCPCs. According to the PCR data, the 
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pretreated adult hCPCs did not upregulate PIK3CA mRNA transcripts to the 
same extent as the pretreated neonatal hCPCs. This suggests that the Akt 
pathway is not sufficiently activated by short-term hypoxia in adult hCPCs and 
may explain why only the neonatal clones displayed significantly elevated p-Akt 
and enhanced invasion capacity. 
Furthermore, depending on the cell type, hypoxic exposure may either 
enhance proliferation (Grayson et al., 2007; Kook et al., 2008; Studer et al., 
2000; van Oorschot et al., 2011), lead to G1 arrest (Gardner et al., 2001; Koshiji 
et al., 2004; Utting et al., 2006), or influence the differentiation process (Lin, Lee, 
& Yun, 2006; Studer et al., 2000; Utting et al., 2006). After treatment with 
hypoxia, human mesenchymal stem cells acquire enhanced proliferative abilities 
(Grayson et al., 2007) while, on the other hand, murine embryonic fibroblasts 
encounter G1 arrest (Gardner et al., 2001). Ideally, in the early stages after 
transplantation, donor cells must survive, continue to divide, migrate to the 
damaged myocardium, and remain multipotent as they engraft. Isl-1+ c-Kit+ 
hCPCs indeed migrate more readily, progress normally through the cell cycle, 
and retain expression of pluripotency markers after short-term hypoxic treatment. 
The results reported here using Isl-1+ c-Kit+ hCPC clones are in line with those 
of other cardiovascular progenitors (Hu et al., 2014; van Oorschot et al., 2011), 
suggesting that pretreatment with short-term hypoxia will enhance functional 
efficacy. Short-term hypoxia yielded mild improvements in adult CPCs, procured 
significant benefit to neonatal CPCs, and therefore, is a promising method for 
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improving cellular function. However, it is important to acknowledge that the most 
significant results were obtained in the neonatal group – enhanced Akt activation, 
upregulated pro-survival transcripts (RELA, HSP70), and improved invasion 
capabilities. Additional work is required to maximize the stimulation of adult 
hCPCs to mirror the function of neonatal CPCs and, in the process, optimize 
autologous adult CPCs for superior transplantation.  Nevertheless, the results 
presented here demonstrate that outcomes of surgical procedures involving 
neonatal CPCs – for the treatment of CHDs or for transplant in HLA-matched 
adult patients – may be improved by preconditioning donor cells using short-term 
hypoxia. 
 
Conclusions 
Short-term hypoxia, as a pretreatment, is a viable approach for supporting 
cell survival and enhancing migratory capabilities in neonatal Isl-1+ c-Kit+ 
hCPCs. While the benefits accrued by adult Isl-1+ c-Kit+ hCPCs via 
preconditioning were reserved in comparison to neonatal clones, the applicability 
of neonatal CPCs in the clinical setting is significant and, therefore, hypoxia-
preconditioned Isl-1+ c-Kit+ hCPCs warrant further investigation in animal 
models. The positive effects of short-term hypoxia include: 1) enhanced 
chemotaxis, which would render the cells more likely to reach damaged tissues 
and successfully engraft, and 2) elevated levels of PIK3CA, HSP70, RELA, and 
HMOX1 mRNA transcripts, which are important for cellular signaling and survival. 
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These findings, if implemented in vivo, may improve cardiac repair after 
infarction. Thus, in order to validate the efficacy of short-term hypoxia as an 
effective pretreatment strategy to optimize cell-based repair, future in vivo 
experiments comparing the performance of hypoxia-preconditioned CPCs to non-
treated CPCs are currently in the design phase.  
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APPENDIX A 
FIGURES 
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Figure 1. Expression of early progenitor markers within a representative clonal hCPC population.  
(A) Isl-1 and c-Kit expression within a representative clonal hCPC population as measured by 
flow cytometry. Dotted lines indicate isotype controls and solid lines indicate Isl-1 or c-Kit 
antibody-labeled hCPC. Double-labeled cells are shown in dot-plot. (B) Expression of stem cell 
markers in a representative Isl-1+ c-Kit+ hCPC clone is shown here by electrophoresis of PCR 
products. MW = molecular weight marker. 
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Figure 2. Short-term hypoxia upregulates phosphorylation of Akt in Isl-1+ c-Kit+ hCPCs. (A) Adult 
and neonatal Isl-1+ c-Kit+ hCPCs exposed to short-term hypoxia were compared to their 
respective normoxic control via qRT-PCR (n = 8). Quantification of results revealed that hypoxia 
preconditioning yields significant upregulation of PIK3CA transcripts within both age groups. 
Additionally, electrophoresis of PIK3CA primer products confirms PCR amplification of the target 
gene segment. Subsequently, phosphorylation of Akt was then measured in preconditioned Isl-1+ 
c-Kit+ hCPCs and their respective controls by flow cytometry. (B) Representative histogram of 
increased p-Akt monoclonal antibody binding after exposure to six hours of hypoxia. (C) 
Quantification of seven independent hCPCs revealed significantly increased (15.4%, p = 0.019) 
Akt phosphorylation in hypoxia-pretreated neonatal groups. Adult clones displayed modest Akt 
activation, but was deemed non-significant after further investigation. 
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Figure 3. Hypoxia-induced Akt activation in adult Isl-1+ c-Kit+ hCPCs. (A) Protein immunoblots 
depicting Akt and p-Akt protein bands from normoxic and hypoxic representative adult hCPC 
samples. (B) Percentage of phosphorylated Akt in total Akt of non-treated and pretreated adult 
hCPC protein – quantified using ImageJ. (C) Western blots illustrating β-Actin and p-Akt protein 
from a representative normoxic adult clone, a SDF-1α-treated normoxic adult clone, and an adult 
clone treated with both SDF-1α and hypoxia. (D) Fold change of phosphorylated Akt, relative to 
β-Actin, was quantified using ImageJ. 
 
0
1
2
3
1
F
o
ld
 C
h
a
n
g
e
p-Akt
Control
SDF
SDF+H
*
B 
   Akt       p-Akt 
      MW      N       H     CTR               MW        N         H         CTR   
0%
5%
10%
15%
20%
Normoxic Hypoxic
p
-A
k
t/
A
k
t 
(%
)
β-Actin 
p-Akt 
SDF 
Control 
SDF & 
Hypoxia 
SDF 
Treated 
Untreated 
Control 
C 
D 
A 
36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Invasion capabilities of Isl-1+ c-Kit+ hCPCs in response to SDF-1α. (A) Quantification of 
hCPC performance in Transwell® invasion assay as influenced by duration of hypoxic exposure. 
Cell numbers were measured by calcein AM in quadruplicate using a representative Isl-1+ c-Kit+ 
hCPC. A significant increase in cell number was noted for each time point, with six hours of 
hypoxia yielding the greatest improvement. (B) Pooled data from both adult and neonate Isl-1+ c-
Kit+ hCPCs, after six hours of hypoxia, show that hypoxia-pretreated hCPCs exhibit significantly 
improved invasion (n = 10, p = 0.017). (C) Invasion assay results organized by age group reveals 
that benefits afforded by hypoxia are age dependent. Adult hCPCs exhibited slight enhancements 
of their invasion capabilities, but only neonatal hCPCs procured statistically significant 
improvements. 
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Figure 5. Transcription of heat shock proteins (HSPs) in response to short-term hypoxia. (A) Fold 
change of HSP mRNAs in adult Isl-1+ c-Kit+ hCPCs resulting from pretreatment with short-term 
hypoxia (n = 4). (B) Neonatal Isl-1+ c-Kit+ hCPC HSP mRNA expression reveals a significant 
two-fold elevation of HSP70 in response to short-term hypoxia (p = 0.022, n = 5). (C) PCR 
products of HSP mRNAs upregulated in adult and neonatal hCPCs, as visualized by agarose gel 
electrophoresis, validate the significant increase of HSP70 in neonatal hCPCs after short-term 
hypoxic preconditioning. MW = molecular weight marker, N = normoxic, H = hypoxic.  
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Figure 6. Select genes associated with cell survival are elevated in response to short-term 
hypoxia. (A) Expression of mRNA transcripts associated with cell survival in adult Isl-1+ c-Kit+ 
hCPCs and relative fold changes after hypoxic exposure. BCL2 and HMOX1 are strongly 
upregulated in response to hypoxia, but the changes are not statistically significant (n = 3). (B) 
Neonatal Isl-1+ c-Kit+ hCPC pro-survival gene expression in response to short-term hypoxia. 
RELA and HMOX1 are elevated in response to short-term hypoxia, but only RELA is significant (p 
= 0.02, n = 3). 
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Figure 7. Programmed cell death in response to oxidative damage is not significantly reduced. 
Using 0.5 mM H2O2, apoptosis was induced in non-treated and preconditioned Isl-1+ c-Kit+ 
hCPCs of both adult and neonatal origin. Relative DNA fragmentation was measured using Brd-U 
and anti-BrdU antibody. (A) Cytometric analysis of BrdU-DNA binding within a representative 
clone is shown here, with and without hypoxic pretreatment. The group treated with short-term 
hypoxia exhibited an approximate 50% decrease in apoptotic cells after induction of cellular death 
by 0.5 mM H2O2. (B) Quantification of TUNEL assay results obtained using three independent 
adult clones are pictured here, showing that apoptosis is not significantly reduced (p = 0.89). (C) 
Pooled results of TUNEL assay for three neonatal clones with and without hypoxic pretreatment. 
Apoptosis in response to oxidative stress trends downward in the hypoxia preconditioned group 
but not to a significant degree (p = 0.34). 
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Figure 8. Isl-1+ c-Kit+ hCPCs maintain expression of early differentiation markers after hypoxic 
exposure. Quantitative RT-PCR was used to examine the effects of short-term hypoxia on the 
expression of differentiation markers present in cardiovascular progenitors. (A) Pooled PCR 
results from three individual adult hCPC clones reveals no significant change in differentiation 
markers with the exception of PDGFRA (1.4-fold increase, p = 0.004). (B) Quantification of PCR 
data from four independent neonatal clones reveals a similar upregulation of PDGFRA (1.8-fold, p 
= 0.0003), as well as a decrease in Brachyury transcripts (0.58-fold, p = 0.004).  
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Figure 9. Short-term hypoxia does not alter normal cell cycle progression. Preconditioned Isl-1+ 
c-Kit+ hCPCs, of both neonate and adult origin, were stained using propidium iodide and 
compared to their respective normoxic controls via flow cytometry. (A) Flow cytometry histogram 
of cell cycle analysis in a representative clonal population, both with and without hypoxic 
pretreatment. (B) Quantification of nine individual results from three independent adult clones 
reveals that short-term hypoxia does not significantly affect normal cell cycle progression in adult 
Isl-1+ c-Kit+ hCPCs. (C) Quantification of data from six technical replicates using three 
independent neonatal clones confirms that normal cell cycle progression is also unaffected by 
short-term hypoxia in neonatal Isl-1+ c-Kit+ hCPCs. 
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